Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.

Myotonic Disorders Clinical Trial

Official title:

Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients With Myotonic Disorders Who Have Completed the MEX-NM-301 Study.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04622553
• Other study ID #: MEX-NM-303
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 5, 2021
• Est. completion date: March 12, 2026

Study information

• Verified date: May 2024
• Source: Lupin Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed the MEX-NM-301 study.

Description:

This is an open-label extension study evaluating the long-term efficacy and safety of mexiletine in paediatric patients with myotonic disorders who have completed the initial parent paediatric study with mexiletine (Protocol No. MEX-NM-301 (PIP Study 4) for children and adolescents aged 6 to < 18 years and who continue to meet the eligibility criteria.

Patients who meet the eligibility criteria and provide consent for this study will be enrolled sequentially by decreasing age groups. Patients aged 12 to < 18 years will enter first as this is the first cohort expected to complete the parent study PIP Study 4 based on top down recruiting. Once initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, patients aged 6 to <12 years will be first enrolled in PIP Study 4 and subsequently this study (PIP Study 7).

Enrolled patients will receive mexiletine at a dose determined in the parent study. Dosing is determined according to body weight and tolerability.

The study includes 9 clinic visits - V1 (baseline), and V2 to V9 every 3 months, approximately, thereafter.

The total duration of study will be 24 months per patient. End-of-treatment (EOT) visit will occur at 24 months or in accordance with the availability of product. The overall study duration would be approximately 5 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 14
• Est. completion date: March 12, 2026
• Est. primary completion date: January 26, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

1. Patients previously completed the parent study PIP study 4 (MEX-NM-301) and tolerated the Mexiletine in the study.

2. Able and willing to provide assent to study participation and a parent or legal guardian willing to sign written informed consent prior to study entry.

3. Patients continue to meet inclusion criteria of parent study (MEX-NM-301):

• No significant cardiac abnormalities as determined by a cardiologist's assessment of the ECG and Echocardiogram

• No history or evidence of any significant liver disorder Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within normal range, or showing no clinically relevant abnormal values, as judged by the Investigator

• Female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or have a vasectomized partner or are practicing abstinence

Exclusion Criteria:

1. Clinically significant laboratory abnormality, ECG or other clinical findings on physical examination indicative of a clinically significant exclusionary disease as determined by the investigator

2. Any contra-indication to mexiletine (as described in the Namuscla Summary of Product Characteristics [SmPC])

• Hypersensitivity to the active substance, or to any of the excipients

• Hypersensitivity to any local anaesthetic

• Ventricular tachyarrhythmia

• Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (= 200 ms) and/or wide QRS complex (= 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),

• QT interval > 450ms

• Myocardial infarction (acute or past), or abnormal Q-waves

• Symptomatic coronary artery disease

• Heart failure with ejection fraction <50%

• Atrial tachyarrhythmia, fibrillation or flutter

• Sinus node dysfunction (including sinus rate < 50 bpm)

• Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.

• Co-administration with medicinal products with narrow therapeutic index

3. Co- administration with antiarrhythmics

4. Any other neurological or psychiatric condition that might affect the assessment of the study measurements

5. Any concurrent illness, or medications which could affect the muscle function

6. Seizure disorder, diabetes mellitus requiring treatment by insulin

7. Pregnant or breastfeeding

8. Concurrent participation in any other clinical trial.

Related Conditions & MeSH terms

• Myotonic Disorders

Intervention

Drug:
• Mexiletine
Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to < 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Cohort 2- (patients aged 6 to < 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1

Locations

Country	Name	City	State
France	Hôpital Necker-Enfants-Malades	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Lupin Ltd.

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the long-term safety and tolerability of mexiletine by AEs	Assess the long-term safety and tolerability of mexiletine in paediatric patients by number and frequency of AEs/SAEs, throughout the study while on treatment	Approximately 24 months
Primary	Assess the long-term safety and tolerability of mexiletine by hand relaxation	Mean time (in seconds) to relaxation of hand muscles and reduction in relaxation time from the first to the fifth contraction	Approximately 24 months
Primary	Assess the long-term safety and tolerability of mexiletine measurement of AESI	Assess the long-term safety and tolerability of mexiletine in paediatric patients by Incidence of adverse events of special interest (AESI),	Approximately 24 months
Primary	Assess the long-term safety and tolerability of mexiletine by changes in ECG	Assess the long-term safety and tolerability of mexiletine in paediatric patients by changes in ECG assessments from baseline, repeated at each study visit	Approximately 24 months
Primary	Assess the long-term safety and tolerability of mexiletine by muscle stiffness	Score for muscle stiffness (myotonia severity) as self-reported by the patients on a Visual Analog Scale (VAS) or Faces scale	Approximately 24 months
Secondary	Mean change in VAS	Mean change in VAS (8 to < 18 years) or Faces (6 to < 8 years) score for severity of muscle stiffness (if not a primary endpoint) pain, weakness and fatigue (every 3 months).	Approximately 24 months
Secondary	Clinical myotonia assessment	Mean change in time to open the eyes after forced eye closure as measured on a stopwatch (when eyelid myotonia present)	Approximately 24 months
Secondary	Mean change in health-related quality-of-life	Mean change in health-related quality-of-life as measured by the Paediatric Quality of Life (PedsQL) score (secondary endpoint for patients aged 6 years to <18 years; every 6 months).	Approximately 24 months
Secondary	Clinical Global Impression (CGI) scores	Clinical Global Impression (CGI) scores (efficacy and tolerability) evaluated by the patient, a parent or proxy and by the investigator. Measured every 6 months	Approximately 24 months
Secondary	Mean change in Myotonia Behaviour Scale (MBS) scores	Mean change in Myotonia Behaviour Scale (MBS) scores (for patients aged 6 years to < 18 years; measured every 6 months).	Approximately 24 months
Secondary	Mean change in time to perform Timed-up and go (TUG) test	Mean change in time to perform Timed-up and go (TUG) test (patients aged 6 to <18 years only)	Approximately 24 months